Christer Sederholm
About
Christer Sederholm is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology.
According to data from OpenAlex, Christer Sederholm has authored 24 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 15 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in Christer Sederholm's work include Lung Cancer Treatments and Mutations (15 papers), Lung Cancer Research Studies (14 papers) and Lung Cancer Diagnosis and Treatment (9 papers). Christer Sederholm is often cited by papers focused on Lung Cancer Treatments and Mutations (15 papers), Lung Cancer Research Studies (14 papers) and Lung Cancer Diagnosis and Treatment (9 papers). Christer Sederholm collaborates with scholars based in Sweden, Norway and United States. Christer Sederholm's co-authors include Jan Nyman, Lars Ekberg, Kristina Nilsson, Signe Friesland, Rolf Lewensohn, Giovanna Gagliardi, Ingmar Lax, Pia Baumann, Lena Wittgren and Nina Jackson Levin and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.
In The Last Decade
Christer Sederholm
24 papers receiving 1.4k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Christer Sederholm Sweden | 14 | 1.2k | 559 | 550 | 347 | 171 | 24 | 1.5k | ||
| Melenda Jeter United States | 21 | 1.2k 1.0× | 612 1.1× | 357 0.6× | 481 1.4× | 103 0.6× | 50 | 1.6k | ||
| Ljubiša Aćimović Serbia | 15 | 963 0.8× | 315 0.6× | 793 1.4× | 125 0.4× | 270 1.6× | 31 | 1.4k | ||
| Farkhad Manapov Germany | 20 | 915 0.8× | 292 0.5× | 540 1.0× | 440 1.3× | 147 0.9× | 107 | 1.3k | ||
| Joseph P. Concannon United States | 18 | 936 0.8× | 282 0.5× | 596 1.1× | 333 1.0× | 169 1.0× | 42 | 1.5k | ||
| J. Knegjens Netherlands | 12 | 599 0.5× | 247 0.4× | 522 0.9× | 237 0.7× | 360 2.1× | 28 | 1.0k | ||
| John Armstrong Ireland | 20 | 600 0.5× | 375 0.7× | 495 0.9× | 271 0.8× | 50 0.3× | 61 | 1.4k | ||
| Hyung Jun Yoo South Korea | 17 | 522 0.5× | 463 0.8× | 262 0.5× | 235 0.7× | 161 0.9× | 34 | 1.2k | ||
| Carles Escriu United Kingdom | 9 | 1.5k 1.3× | 149 0.3× | 786 1.4× | 424 1.2× | 56 0.3× | 29 | 1.9k | ||
| R. Bryan Barriger United States | 10 | 1.2k 1.0× | 715 1.3× | 214 0.4× | 651 1.9× | 34 0.2× | 19 | 1.4k | ||
| Hubert de Crémoux France | 19 | 806 0.7× | 115 0.2× | 410 0.7× | 66 0.2× | 204 1.2× | 48 | 1.2k |
Countries citing papers authored by Christer Sederholm
Since
Specialization
Citations
This map shows the geographic impact of Christer Sederholm's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christer Sederholm with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christer Sederholm more than expected).
Fields of papers citing papers by Christer Sederholm
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Christer Sederholm. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christer Sederholm. The network helps show where Christer Sederholm may publish in the future.
Co-authorship network of co-authors of Christer Sederholm
This figure shows the co-authorship network connecting the top 25 collaborators of Christer Sederholm. A scholar is included among the top collaborators of Christer Sederholm based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christer Sederholm. Christer Sederholm is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Dittrich, Christian, Zsolt Pápai-Székely, Núria Viñolas, et al.. (2014). A randomised phase II study of pemetrexed versus pemetrexed+erlotinib as second-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer. European Journal of Cancer. 50(9). 1571–1580.
2.
Sörenson, Sverre, Helena Fohlin, Andrea Lindgren, et al.. (2012). Predictive role of plasma vascular endothelial growth factor for the effect of celecoxib in advanced non-small cell lung cancer treated with chemotherapy. European Journal of Cancer. 49(1). 115–120.
3.
Koch, Andrea, Bengt Bergman, Erik Holmberg, et al.. (2011). Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: A double blind randomised clinical phase III trial (CYCLUS study) by the Swedish Lung Cancer Study Group. European Journal of Cancer. 47(10). 1546–1555.
4.
Wennberg, Berit, Pia Baumann, Giovanna Gagliardi, et al.. (2011). NTCP modelling of lung toxicity after SBRT comparing the universal survival curve and the linear quadratic model for fractionation correction. Acta Oncologica. 50(4). 518–527.
5.
Pawel, Joachim von, Zsolt Pápai-Székely, Núria Viñolas, et al.. (2011). A randomized phase II study of pemetrexed versus pemetrexed plus erlotinib in second-line treatment for locally advanced or metastatic, nonsquamous NSCLC.. Journal of Clinical Oncology. 29(15_suppl). 7526–7526.
6.
Hallqvist, Andreas, Gunnar Wagenius, H. Rylander, et al.. (2010). Concurrent cetuximab and radiotherapy after docetaxel–cisplatin induction chemotherapy in stage III NSCLC: Satellite—A phase II study from the Swedish Lung Cancer Study Group. Lung Cancer. 71(2). 166–172.
7.
Hillerdal, Gunnar, Christer Sederholm, & Kerstin Andersson. (2010). Randomized phase II study of gemcitabine and carboplatin +/− sequential docetaxel in non-small cell lung cancer. Lung Cancer. 71(2). 178–181.
8.
Nyman, Jan, Andreas Hallqvist, Ola Brodin, et al.. (2009). Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: a phase II study from the Swedish Lung Cancer Study Group. Journal of Thoracic Oncology. 4(9). 373–373.
9.
Tell, Roger, Christer Sederholm, Claes Klintenberg, et al.. (2009). Multicentre phase II trial of paclitaxel and carboplatin with concurrent radiotherapy in locally advanced non-small cell lung cancer.. PubMed. 28(5B). 2851–7.
10.
Nyman, Jan, Signe Friesland, Andreas Hallqvist, et al.. (2008). How to improve loco-regional control in stages IIIa–b NSCLC?. Lung Cancer. 65(1). 62–67.
11.
Baumann, Pia, Jan Nyman, Morten Høyer, et al.. (2008). Stereotactic body radiotherapy for medically inoperable patients with stage I non-small cell lung cancer – A first report of toxicity related to COPD/CVD in a non-randomized prospective phase II study. Radiotherapy and Oncology. 88(3). 359–367.
12.
Hermes, Andreas, Bengt Bergman, Roy M. Bremnes, et al.. (2008). Irinotecan Plus Carboplatin Versus Oral Etoposide Plus Carboplatin in Extensive Small-Cell Lung Cancer: A Randomized Phase III Trial. Journal of Clinical Oncology. 26(26). 4261–4267.
13.
Hermes, Andreas, Bengt Bergman, Roy M. Bremnes, et al.. (2007). A randomized phase III trial of irinotecan plus carboplatin versus etoposide plus carboplatin in patients with small cell lung cancer, extensive disease (SCLC-ED): IRIS-Study. Journal of Clinical Oncology. 25(18_suppl). 7523–7523.
14.
Reck, Martin, Harry J.M. Groen, H. Riska, et al.. (2006). Initial safety results of an expanded access program (EAP) of erlotinib in non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 24(18_suppl). 7190–7190.
15.
Sederholm, Christer. (2002). Gemcitabine versus gemcitabine/carboplatin in advanced non–small cell lung cancer: Preliminary findings in a phase III trial of the Swedish Lung Cancer Study Group. Seminars in Oncology. 29(3). 50–54.
16.
Helsing, Martin, Lars Thaning, Christer Sederholm, et al.. (1999). Treatment with paclitaxel 1-h infusion and carboplatin of patients with advanced non-small-cell lung cancer: a phase II multicentre trial. Lung Cancer. 24(2). 107–113.
17.
Hellquist, Henrik, et al.. (1997). Fas receptor is expressed in human lung squamous cell carcinomas, whereas bcl-2 and apoptosis are not pronounced: a preliminary report. British Journal of Cancer. 76(2). 175–179.
18.
Manegold, C., Bengt Bergman, A. Chemaissani, et al.. (1997). Single-agent gemcitabine versus cisplatin-etoposide: Early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer. Annals of Oncology. 8(6). 525–529.
19.
Manegold, C., P. Drings, Joachim von Pawel, et al.. (1997). A randomized study of gemcitabine monotherapy versus etoposide/cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer.. PubMed. 24(3 Suppl 8). S8–13.
20.
Sörensen, Jan, Pia Forsberg, Erik Håkanson, et al.. (1989). A New Diagnostic Approach to the Patient with Severe Pneumonia. Scandinavian Journal of Infectious Diseases. 21(1). 33–41.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Melenda Jeter Breakdown of academic impact, for papers by Ljubiša Aćimović Breakdown of academic impact, for papers by Farkhad Manapov Breakdown of academic impact, for papers by Joseph P. Concannon Breakdown of academic impact, for papers by J. Knegjens Breakdown of academic impact, for papers by John Armstrong Breakdown of academic impact, for papers by Hyung Jun Yoo Breakdown of academic impact, for papers by Carles Escriu Breakdown of academic impact, for papers by R. Bryan Barriger Breakdown of academic impact, for papers by Hubert de Crémoux